PDS Biotechnology Engages in $11.1 Million Direct Stock Sale
PDS Biotechnology Corporation (NASDAQ: PDSB), a notable player in the field of immunotherapy, has made significant strides recently by entering into a securities purchase agreement. This agreement allows them to sell 5,800,000 shares of common stock at a set price of $0.91 per share. Along with these shares, they are offering warrants enabling the purchase of an additional 5,800,000 shares.
Details of the Offering
The warrants included in the offering will be exercisable at a price of $1.00 per share. Investors will be able to exercise these warrants starting six months after issuance, with an expiration date set five years after the initial exercise date. The completion of this direct offering is anticipated to close shortly, fulfilling standard closing conditions.
Fund Allocation from the Offering
The anticipated gross proceeds from this transaction are projected to be around $5.3 million before any placements fees or other related expenses. An additional potential funding of $5.8 million could arise from the full cash exercise of the accompanying warrants. The proceeds are earmarked primarily for the ongoing VERSATILE-003 Phase 3 clinical trial after discussions with the FDA on adjusting the trial protocol to facilitate a quicker approval pathway for their lead therapy, PDS0101.
Current Financial Position
As of the end of September, PDS Biotechnology reported approximately $26.2 million in cash and cash equivalents. This figure is based on internal records and may be subject to adjustments as financial closing procedures are finalized. Thus, the actual results may differ from this preliminary estimate.
Registration Statement Details
This offering is being conducted under a shelf registration statement on Form S-3, previously filed with the SEC and ratified in September. The securities involved will be distributed according to a prospectus that will be filed with the SEC, ensuring compliance with regulatory obligations.
Warrants Amendments
In addition, PDS Biotechnology intends to amend existing warrants that allow the purchase of up to 5,948,334 common stock shares, currently set at an exercise price of $1.50. Once the current offering closes, these warrants will be adjusted to an exercise price of $1.00.
About PDS Biotechnology
At its core, PDS Biotechnology is devoted to revolutionizing the way the immune system combats cancer. The company is examining advanced methodologies for its targeted immunotherapy, PDS0101, particularly in treating HPV16-positive head and neck cancers. This innovative approach integrates conventional immune checkpoint inhibitors and novel treatment strategies involving PDS01ADC, an antibody-drug conjugate.
Investor Relations
PDS Biotech's emphasis on clinical innovation provides a robust framework for its financial strategies, opening avenues for investment and expansion. Investors interested in learning more can reach out to designated contacts within the company.
Contact Information
For investor queries, Mike Moyer of LifeSci Advisors is available at +1 (617) 308-4306. Media inquiries can be directed to David Schull at Russo Partners by calling +1 (858) 717-2310.
Frequently Asked Questions
What is the purpose of PDS Biotechnology's recent offering?
The proceeds from the offering are intended for ongoing clinical trials and other corporate purposes.
What are the key financial details related to the offering?
PDS Biotechnology aims to raise approximately $5.3 million initially, potentially increasing by another $5.8 million through warrant exercises.
What is PDS0101, and why is it significant?
PDS0101 is a lead investigational targeted immunotherapy developed by PDS Biotechnology, aimed at treating specific cancers.
Who can be contacted for more information about PDS Biotechnology?
Mike Moyer and David Schull are the primary contacts for investor and media inquiries, respectively.
How does the amendment of existing warrants affect investors?
The amendment reduces the exercise price of the existing warrants, potentially making them more attractive for investors.
